Skip to main content
OpenTrials
Completed

NCT Number: NCT05921591

Safety, Tolerability, and Pharmacokinetics of IRL201104 in Healthy Volunteers

The purpose of this clinical study is to assess the safety, tolerability and pharmacokinetics of repeat doses of IRL201104 given to healthy volunteers.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Revolo Phase I site

Los Angeles, California, 90630, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • Participants must provide signed informed consent.
  • Participants must be in good general health.
  • Body mass index (BMI) 18 to ≤ 30 kg/m2.
  • Contraception use by men or women .

Key Exclusion Criteria:

  • Clinically significant liver, kidney disease or cardiac disease.
  • Active malignancy and/or history of malignancy in the past 5 years.
  • Serious local or systemic infection within 30 days prior to Screening
  • Any acute illness within 30 days prior to Day 1.
  • Surgery, bone fracture or major musculoskeletal injury within the 3 months.
  • Abnormal screening laboratory tests.
  • Positive for human immunodeficiency virus (HIV) antibody or antigen.
  • Positive hepatitis C virus (HCV) antibody or positive hepatitis B surface antigen (HBsAg).
  • Positive result indicating active SARS-CoV-2 infection on Day -1.
  • Positive urine drug screen/alcohol breath test at Screening.
  • Positive Quantiferon Tuberculosis (TB) test.
  • Systolic blood pressure (BP) > 150 mmHg or < 90 mmHg or diastolic BP > 90 mmHg or < 50 mmHg. Heart rate < 40 beats per minute (bpm) or > 100 bpm.
  • Prolonged QT interval corrected by Fridericia's formula (QTcF) (> 450 ms for males and > 470 ms for females), cardiac arrhythmia, or any clinically significant abnormality in the resting electrocardiogram (ECG), as judged by the Investigator.
  • All prescription and over-the-counter medications (including herbal medications), except for contraceptives and hormonal replacement therapy (HRT), are prohibited within 7 days prior to the first study intervention administration and throughout the entire duration of the study.
  • All vaccines within 30 days prior and throughout the entire duration of the study.
  • Administration of investigational product in another study within 30 days prior to the first study intervention administration, or five half-lives, whichever is longer.
  • Blood donation within 30 days prior to the first study intervention administration.
  • Females who are pregnant or breastfeeding.
  • Failure to satisfy Investigator of fitness to participate for any other reason.
  • Cigarette smokers and users of nicotine-containing products.

Treatment and study plan

IRL201104

Drug

Lyophilised powder for reconstitution for IV dosing

Placebo

Drug

Matching placebo for IRL201104

Primary outcomes

  1. Treatment Emergent Adverse Events

    Time frame: 28 days

    Number of subjects experiencing TEAE and number of TEAE will be summarised by treatment

Secondary outcomes

  1. PK parameters of IRL201104 concentration in plasma

    Time frame: 28 days

    Individual plasma levels will be listed and summarized by treatment and collection timepoint.

Other outcomes

  1. Incidence of treatment-emergent anti-drug antibody (ADA) responses

    Time frame: 28 days

    The presence of ADAs to IRL201104 will be listed and summarized by treatment group and timepoint.

Sponsors and collaborators

Lead sponsor

Revolo Biotherapeutics

Industry

Registry information

Official study title

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of IRL201104 in Healthy Volunteers

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Jun 27, 2023
Registry last updated
Sep 28, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.